[Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design]
Standard
[Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design]. / Cracowski, J L; Yaici, A; Sitbon, O; Reynaud-Gaubert, M; Renversez, J C; Pison, C; Faure, P; Cracowski, C; Chouri, N; Chaouat, A; Chabot, F; Schwedhelm, Edzard; Maas, Renke; Degano, B; Mornex, J F; Humbert, M.
in: REV MAL RESPIR, Jahrgang 21(6 Pt 1), 2004, S. 1137-1143.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design]
AU - Cracowski, J L
AU - Yaici, A
AU - Sitbon, O
AU - Reynaud-Gaubert, M
AU - Renversez, J C
AU - Pison, C
AU - Faure, P
AU - Cracowski, C
AU - Chouri, N
AU - Chaouat, A
AU - Chabot, F
AU - Schwedhelm, Edzard
AU - Maas, Renke
AU - Degano, B
AU - Mornex, J F
AU - Humbert, M
PY - 2004
Y1 - 2004
N2 - CURRENT SITUATION: Pulmonary arterial hypertension (PAH) is a serious disease. Its prognostic is based on the functional status quantified by the NYHA class and the 6-min walking test, and the hemodynamic data. The algorithms of treatment are solely based on the hemodynamic data and the functional status. The main objective is to test whether basal concentrations of isoprostanes, Big endotheline 1, ADMA, high sensitivity CRP, NT-Pro-BNP and cardiac troponin T are a 3-year prognostic factor in PAH using a combined criterion: death from any cause and pulmonary or cardiopulmonary transplantation. MATERIALS AND METHODS: This is a multicenter, prospective, prognostic, single blinded study (plasma and urinary samples being blinded). The study started in november 2003, running for 2 years, with a 3 year follow-up for each patient. The main inclusion criterion is PAH. The data analysis will use a multivariable Cox model, taking into account the functional and hemodynamic parameters. EXPECTED RESULTS: This study will determine whether any of the biomarkers tested provides additional prognostic information in PAH in addition to the functional and hemodynamic parameters.
AB - CURRENT SITUATION: Pulmonary arterial hypertension (PAH) is a serious disease. Its prognostic is based on the functional status quantified by the NYHA class and the 6-min walking test, and the hemodynamic data. The algorithms of treatment are solely based on the hemodynamic data and the functional status. The main objective is to test whether basal concentrations of isoprostanes, Big endotheline 1, ADMA, high sensitivity CRP, NT-Pro-BNP and cardiac troponin T are a 3-year prognostic factor in PAH using a combined criterion: death from any cause and pulmonary or cardiopulmonary transplantation. MATERIALS AND METHODS: This is a multicenter, prospective, prognostic, single blinded study (plasma and urinary samples being blinded). The study started in november 2003, running for 2 years, with a 3 year follow-up for each patient. The main inclusion criterion is PAH. The data analysis will use a multivariable Cox model, taking into account the functional and hemodynamic parameters. EXPECTED RESULTS: This study will determine whether any of the biomarkers tested provides additional prognostic information in PAH in addition to the functional and hemodynamic parameters.
M3 - SCORING: Zeitschriftenaufsatz
VL - 21(6 Pt 1)
SP - 1137
EP - 1143
ER -
